SI-053

Double Bond Pharmaceutical AB · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	SI-053
Sponsor	Double Bond Pharmaceutical AB
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SI-053 CI brief — competitive landscape report
SI-053 updates RSS · CI watch RSS
Double Bond Pharmaceutical AB portfolio CI